UY36250A - Forma cristalina de sofosbuvir y proceso para su preparación - Google Patents
Forma cristalina de sofosbuvir y proceso para su preparaciónInfo
- Publication number
- UY36250A UY36250A UY0001036250A UY36250A UY36250A UY 36250 A UY36250 A UY 36250A UY 0001036250 A UY0001036250 A UY 0001036250A UY 36250 A UY36250 A UY 36250A UY 36250 A UY36250 A UY 36250A
- Authority
- UY
- Uruguay
- Prior art keywords
- sofosbuvir
- preparation
- crystal form
- production
- pharmaceutical compositions
- Prior art date
Links
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 title abstract 2
- 229960002063 sofosbuvir Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01L—MEASURING FORCE, STRESS, TORQUE, WORK, MECHANICAL POWER, MECHANICAL EFFICIENCY, OR FLUID PRESSURE
- G01L15/00—Devices or apparatus for measuring two or more fluid pressure values simultaneously
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01L—MEASURING FORCE, STRESS, TORQUE, WORK, MECHANICAL POWER, MECHANICAL EFFICIENCY, OR FLUID PRESSURE
- G01L27/00—Testing or calibrating of apparatus for measuring fluid pressure
- G01L27/002—Calibrating, i.e. establishing true relation between transducer output value and value to be measured, zeroing, linearising or span error determination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01L—MEASURING FORCE, STRESS, TORQUE, WORK, MECHANICAL POWER, MECHANICAL EFFICIENCY, OR FLUID PRESSURE
- G01L27/00—Testing or calibrating of apparatus for measuring fluid pressure
- G01L27/007—Malfunction diagnosis, i.e. diagnosing a sensor defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Forma cristalina a de sofosbuvir, proceso para su producción y su uso en composiciones farmacéuticas
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20141411 | 2014-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36250A true UY36250A (es) | 2016-02-29 |
Family
ID=51628377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036250A UY36250A (es) | 2014-08-01 | 2015-07-31 | Forma cristalina de sofosbuvir y proceso para su preparación |
Country Status (11)
Country | Link |
---|---|
US (2) | US9845335B2 (es) |
EP (1) | EP3174889B1 (es) |
CN (1) | CN106687470A (es) |
AR (1) | AR101368A1 (es) |
BR (1) | BR112017002153A2 (es) |
CA (1) | CA2956869A1 (es) |
ES (1) | ES2773674T3 (es) |
MX (1) | MX2017001487A (es) |
TW (1) | TW201609709A (es) |
UY (1) | UY36250A (es) |
WO (1) | WO2016016327A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3845221T1 (sl) | 2014-06-13 | 2024-03-29 | Ratiopharm Gmbh | Trdne oblike sofosbuvirja |
WO2016156512A1 (en) * | 2015-04-01 | 2016-10-06 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
US10738071B2 (en) * | 2016-03-17 | 2020-08-11 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
CN106496295A (zh) * | 2016-10-19 | 2017-03-15 | 上海博志研新药物技术有限公司 | 索非布韦晶型6的制备方法 |
EP3661944A1 (en) | 2017-08-03 | 2020-06-10 | Sandoz AG | Sofosbuvir hydrate |
CN109467577A (zh) * | 2018-12-06 | 2019-03-15 | 南通常佑药业科技有限公司 | 一种索非布韦晶型及无定型产品的制备方法 |
CN109517018B (zh) * | 2018-12-29 | 2021-05-04 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索磷布韦新晶型及其制备方法 |
WO2021203409A1 (zh) * | 2020-04-10 | 2021-10-14 | 南京正大天晴制药有限公司 | 一种用于治疗丙肝的无引湿性低变异性新晶型 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
UY33311A (es) * | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidatos de nucleosidos |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
CN103804446A (zh) * | 2014-02-27 | 2014-05-21 | 苏州东南药业股份有限公司 | 一种3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-γ-内酯的制备方法 |
CZ307789B6 (cs) * | 2014-04-15 | 2019-05-09 | Zentiva, K.S. | Způsob výroby biologicky účinných fosforamidátových léčiv |
CN105153257B (zh) * | 2014-06-12 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 索非布韦的制备方法 |
CN105273022A (zh) * | 2014-06-16 | 2016-01-27 | 深圳翰宇药业股份有限公司 | 一种索非布韦中间体以及由其制备索非布韦的方法 |
CZ2014502A3 (cs) * | 2014-07-17 | 2016-01-27 | Zentiva, K.S. | Nová forma sofosbuviru a způsob její přípravy |
-
2015
- 2015-07-17 TW TW104123244A patent/TW201609709A/zh unknown
- 2015-07-29 CN CN201580049016.4A patent/CN106687470A/zh active Pending
- 2015-07-29 ES ES15754127T patent/ES2773674T3/es active Active
- 2015-07-29 EP EP15754127.7A patent/EP3174889B1/en not_active Revoked
- 2015-07-29 CA CA2956869A patent/CA2956869A1/en not_active Abandoned
- 2015-07-29 AR ARP150102428A patent/AR101368A1/es unknown
- 2015-07-29 US US15/308,253 patent/US9845335B2/en active Active
- 2015-07-29 BR BR112017002153A patent/BR112017002153A2/pt not_active Application Discontinuation
- 2015-07-29 MX MX2017001487A patent/MX2017001487A/es unknown
- 2015-07-29 WO PCT/EP2015/067422 patent/WO2016016327A1/en active Application Filing
- 2015-07-31 UY UY0001036250A patent/UY36250A/es not_active Application Discontinuation
-
2017
- 2017-11-28 US US15/823,782 patent/US20180079771A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170051004A1 (en) | 2017-02-23 |
CA2956869A1 (en) | 2016-02-04 |
ES2773674T3 (es) | 2020-07-14 |
MX2017001487A (es) | 2017-12-15 |
TW201609709A (zh) | 2016-03-16 |
AR101368A1 (es) | 2016-12-14 |
WO2016016327A1 (en) | 2016-02-04 |
US20180079771A1 (en) | 2018-03-22 |
EP3174889B1 (en) | 2019-11-20 |
CN106687470A (zh) | 2017-05-17 |
EP3174889A1 (en) | 2017-06-07 |
US9845335B2 (en) | 2017-12-19 |
BR112017002153A2 (pt) | 2018-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36250A (es) | Forma cristalina de sofosbuvir y proceso para su preparación | |
EP3224012A4 (en) | Methods and compositions for concrete production | |
BR112017009540A2 (pt) | biorreator usando macroalgas | |
EP3013544A4 (en) | Methods and compositions for concrete production | |
DK3077513T3 (da) | Sammensætninger og fremgangsmåder til fremstilling af (r)-retikulin og udgangsstoffer deraf | |
BR112016027595A2 (pt) | Produtos de peptídeos, composição farmacêutica compreendendo um produto de peptídeo, uso de um produto de peptídeo e método para produzir um produto de peptídeo | |
BR112015022347A2 (pt) | composição para vacinação, método para produzir uma composição para vacinação e uso de composição | |
EP3239149A4 (en) | Crystal form i of canagliflozin and preparation method thereof | |
PT2970009T (pt) | Novo clínquer sulfobelítico dopado com fósforo e seu processo de preparação | |
BR112017001384A2 (pt) | composto para uso em tratamento anti-helmíntico | |
PL3237375T3 (pl) | Kryształy prekursorów N-(kwas octowy) alaniny, sposób ich wytwarzania i ich zastosowanie | |
SG11201505385VA (en) | Pharmaceutical composition in the form of a tabletand a method for producing same | |
CL2016003144A1 (es) | Método y composición para mejorar la productividad de plantas no leguminosas | |
EP3239162A4 (en) | Crystallization water-free calcium dibutyryladenosine cyclophosphate crystal form, and preparation method and use thereof | |
GB2559718B (en) | Novel crystalline form of tribenuron-methyl, process for preparation and use thereof | |
ZA201607265B (en) | A process for preparation of levothyroxine and salts thereof | |
PL3223799T3 (pl) | Sposób otrzymywania kompozycji składnik farmaceutyczny-polimer | |
GB201416858D0 (en) | Methods of in Vitro Oocyte Development | |
EP3100734A4 (en) | Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma | |
BR112016024296A2 (pt) | composições e métodos para aumentar a produção | |
GB2561750B (en) | Novel crystalline form of thifensulfuron-methyl, process for preparation and use thereof | |
CO7051029A2 (es) | Proceso para la preparacion de fenilpropanonas sustituidas | |
CO7151540A2 (es) | Método para producir un material no tejido hidroenmarañado | |
TH1501000802A (th) | ระบบเพื่อทำการผลิตผลิตภัณฑ์ขั้นสุดท้ายโดยการตัดก้อนวัสดุแบน โดยเฉพาะอย่างยิ่งก้อนเวเฟอร์แบนและกลวง | |
TH1501006850A (th) | องค์ประกอบของเซนิคริไวรอคและวิธีการสำหรับการผลิตและการใช้สิ่งดังกล่าว |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20220705 |